/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

GEOVAX LABS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.3999 0.0777(7.77%) GOVX at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 0.366
Highest Today 0.41
Today’s Open 0.37
Prev. Close 0.3718
52 Week High 2.75
52 Week Low 0.37
Day’s Range: Low 0.366 High 0.41
52-Week Range: Low 0.37 High 2.75
1 day return -
1 Week return -3.84
1 month return -25.44
3 month return -45.65
6 month return -63.93
1 year return -82.12
3 year return -96.66
5 year return -99.02
10 year return -

Institutional Holdings

UBS Group AG 0.79

Vanguard Institutional Extnd Mkt Idx Tr 0.46

Vanguard Group Inc 0.45

Geode Capital Management, LLC 0.42

Fidelity Extended Market Index 0.27

Morgan Stanley - Brokerage Accounts 0.20

BlackRock Inc 0.11

Spartan Extended Market Index Pool F 0.08

State Street Corp 0.07

Fidelity Series Total Market Index 0.06

Fidelity Total Market Index 0.06

Northern Trust Corp 0.05

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Moneta Group Investment Advisors Inc 0.04

Spartan Total Market Index Pool G 0.03

Extended Equity Market Fund K 0.02

Citigroup Inc 0.02

SBI Securities Co Ltd 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

HARBOUR INVESTMENTS, INC. 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Tower Research Capital LLC 0.01

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Extended Equity Market Fund M 0.00

Bank of America Corp 0.00

Advisor Group Holdings, Inc. 0.00

SSgA U.S. Total Market Index Strategy 0.00

Wells Fargo & Co 0.00

Caitong International Asset Management Co., Limited. 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

FMR Inc 0.00

Jane Street Group LLC 0.00

Quaker Wealth Management, LLC 0.00

Royal Bank of Canada 0.00

Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 11.04 M

PB Ratio 2.2934

PE Ratio 0.0

Enterprise Value 9.76 M

Total Assets 8.16 M

Volume 555044

Company Financials

Annual Revenue FY23:0 0.0M, FY22:81000 0.1M, FY21:385000 0.4M, FY20:1823000 1.8M, FY19:1175896 1.2M

Annual Profit FY23:null 0.0M, FY22:81000 0.1M, FY21:385000 0.4M, FY20:1823000 1.8M, FY19:1175896 1.2M

Annual Net worth FY23:null 0.0M, FY22:-14014561 -14.0M, FY21:-18531479 -18.5M, FY20:-2938344 -2.9M, FY19:-2375124 -2.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:852282 0.9M, Q1/2025:1636863 1.6M, Q3/2024:2789484 2.8M, Q2/2024:300677 0.3M

Quarterly Profit Q3/2025:-16802 -0.0M, Q2/2025:852282 0.9M, Q1/2025:1619942 1.6M, Q3/2024:2789484 2.8M, Q2/2024:-3976191 -4.0M

Quarterly Net worth Q3/2025:-6318914 -6.3M, Q2/2025:-5369783 -5.4M, Q1/2025:-5357651 -5.4M, Q3/2024:-5815468 -5.8M, Q2/2024:-5064042 -5.1M

Fund house & investment objective

Company Information GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. David Alan Dodd

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow